P3 Health Partners (PIII) – Research Analysts’ Weekly Ratings Changes

P3 Health Partners (NASDAQ: PIII) has recently received a number of price target changes and ratings updates:

• 5/28/2026 – P3 Health Partners was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 5/22/2026 – P3 Health Partners had its “hold” rating reaffirmed by TD Cowen. They now have a $14.00 price target on the stock, up from $3.00.
• 5/15/2026 – P3 Health Partners was given a new $14.00 price target by UBS Group AG.
• 5/15/2026 – P3 Health Partners had its “buy” rating reaffirmed by Lake Street Capital. They now have a $14.00 price target on the stock, up from $4.00.
• 4/21/2026 – P3 Health Partners had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/2/2026 – P3 Health Partners had its price target lowered by TD Cowen from $8.00 to $3.00. They now have a “hold” rating on the stock.

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.